Skip to main content
News

Quaisr joins European Innovation Council consortium for digital twins in healthcare

Quaisr and Multiwave Technologies partner with the OMICSENS consortium to develop an omics platform improving NSCLC prognosis.

European Innovation Council

Quaisr is partnering with Multiwave Technologies and the OMICSENS consortium to develop a new omics measurement platform aimed at improving prognosis for non-small cell lung cancer (NSCLC).

As part of this European Innovation Council–funded initiative, Quaisr will deploy scalable platform infrastructure to support advanced machine-learning pipelines. These pipelines will be used by the consortium for analyte identification and quantification, enabling more precise and data-driven insights into NSCLC.

The collaboration brings together expertise in digital twins, omics technologies, and AI-driven analytics to accelerate translational research and improve clinical decision-making.

Full information: omicsens.eu

Announcement: LinkedIn

Project highlights

- Development of an omics measurement platform focused on NSCLC prognosis. - Deployment of Quaisr’s infrastructure for machine-learning pipelines. - Collaboration with Multiwave Technologies and the OMICSENS consortium under the European Innovation Council framework. - Application of digital twins and advanced analytics to support better clinical decision-making.

Talk to an engineer

Schedule a technical deep-dive to discuss your specific simulation stack, HPC security requirements, and data protocols. See exactly how Quaisr fits into your existing architecture.

Book a Demo